Primary Heart Involvement in Systemic Sclerosis, from Conventional to Innovative Targeted Therapeutic Strategies

Overview

Journal J Scleroderma Relat Disord

Date 2022 Oct 10

PMID 36211207

Authors

Arianna Ferlito

Corrado Campochiaro

Alessandro Tomelleri

Lorenzo Dagna

Giacomo De Luca

Affiliations

Soon will be listed here.

Abstract

Primary heart involvement is frequent in systemic sclerosis, even though often sub-clinical, and includes cardiac abnormalities that are predominantly attributable to systemic sclerosis rather than other causes and/or complications. A timely diagnosis is crucial to promptly start the appropriate therapy and to prevent the potential life-threatening early and late complications. There is little evidence on how to best manage systemic sclerosis-primary heart involvement as no specific treatment recommendations for heart disease are available, and a shared treatment approach is still lacking. The objective of this review is to summarize the state of the art of current literature and the overall management strategies and therapeutic approaches for systemic sclerosis-primary heart involvement. Novel insights into pathogenic mechanisms of systemic sclerosis-primary heart involvement are presented to facilitate the comprehension of therapeutic targets and novel treatment strategies.

Citing Articles

Heart involvement in patients with systemic sclerosis-what have we learned about it in the last 5 years.

Nadel A, Nadel M, Taborska N, Stepien B, Gajdecki J, Brzezinska O Rheumatol Int. 2024; 44(10):1823-1836.

PMID: 39192021 PMC: 11393134. DOI: 10.1007/s00296-024-05699-x.

Therapeutic strategies for primary heart involvement in systemic sclerosis.

Batani V, Dagna L, Luca G Rheumatol Immunol Res. 2024; 5(2):72-82.

PMID: 39015843 PMC: 11248560. DOI: 10.1515/rir-2024-0010.

Systemic sclerosis associated myopathy: how to treat.

Selva-OCallaghan A, Guillen-Del-Castillo A, Gil-Vila A, Trallero-Araguas E, Matas-Garcia A, Milisenda J Curr Treatm Opt Rheumatol. 2024; 9(4):151-167.

PMID: 38737329 PMC: 11086655. DOI: 10.1007/s40674-023-00206-y.

Serum markers in systemic sclerosis with cardiac involvement.

Gokcen N Clin Rheumatol. 2023; 42(10):2577-2588.

PMID: 37335406 DOI: 10.1007/s10067-023-06663-z.

References

Zairi I, Mzoughi K, Jnifene Z, Kamoun S, Jabeur M, Ben Moussa F . Speckle tracking echocardiography in systemic sclerosis: A useful method for detection of myocardial involvement. Ann Cardiol Angeiol (Paris). 2018; 68(4):226-231. DOI: 10.1016/j.ancard.2018.08.027. View

Varga J, Abraham D . Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007; 117(3):557-67. PMC: 1804347. DOI: 10.1172/JCI31139. View

Falkenham A, De Antueno R, Rosin N, Betsch D, Lee T, Duncan R . Nonclassical resident macrophages are important determinants in the development of myocardial fibrosis. Am J Pathol. 2015; 185(4):927-42. DOI: 10.1016/j.ajpath.2014.11.027. View

Priori S, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J . 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the.... Europace. 2015; 17(11):1601-87. DOI: 10.1093/europace/euv319. View

Spethmann S, Rieper K, Riemekasten G, Borges A, Schattke S, Burmester G . Echocardiographic follow-up of patients with systemic sclerosis by 2D speckle tracking echocardiography of the left ventricle. Cardiovasc Ultrasound. 2014; 12:13. PMC: 3986623. DOI: 10.1186/1476-7120-12-13. View

Lavine K, Pinto A, Epelman S, Kopecky B, Clemente-Casares X, Godwin J . The Macrophage in Cardiac Homeostasis and Disease: JACC Macrophage in CVD Series (Part 4). J Am Coll Cardiol. 2018; 72(18):2213-2230. PMC: 6209119. DOI: 10.1016/j.jacc.2018.08.2149. View

Mueller K, Mueller I, Eppler D, Zuern C, Seizer P, Kramer U . Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy. PLoS One. 2015; 10(5):e0126707. PMC: 4428754. DOI: 10.1371/journal.pone.0126707. View

Carette S, Turcotte J, Mathon G . Severe myositis and myocarditis in progressive systemic sclerosis. J Rheumatol. 1985; 12(5):997-9. View

Kazzam E, Caidahl K, Hllgren R, Gustafsson R, Waldenstrom A . Non-invasive evaluation of long-term cardiac effects of captopril in systemic sclerosis. J Intern Med. 1991; 230(3):203-12. DOI: 10.1111/j.1365-2796.1991.tb00432.x. View

10.

Furst D, Tseng C, Clements P, Strange C, Tashkin D, Roth M . Adverse events during the Scleroderma Lung Study. Am J Med. 2011; 124(5):459-67. DOI: 10.1016/j.amjmed.2010.12.009. View

11.

Meune C, Vignaux O, Kahan A, Allanore Y . Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis. 2010; 103(1):46-52. DOI: 10.1016/j.acvd.2009.06.009. View

12.

Bernardo P, Conforti M, Bellando-Randone S, Pieragnoli P, Blagojevic J, Kaloudi O . Implantable cardioverter defibrillator prevents sudden cardiac death in systemic sclerosis. J Rheumatol. 2011; 38(8):1617-21. DOI: 10.3899/jrheum.100480. View

13.

Wei Y, Yan X, Yan L, Hu F, Ma W, Wang Y . Inhibition of microRNA‑155 ameliorates cardiac fibrosis in the process of angiotensin II‑induced cardiac remodeling. Mol Med Rep. 2017; 16(5):7287-7296. PMC: 5865857. DOI: 10.3892/mmr.2017.7584. View

14.

Henes J, Koetter I, Horger M, Schmalzing M, Mueller K, Eick C . Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. Rheumatology (Oxford). 2014; 53(5):919-22. DOI: 10.1093/rheumatology/ket464. View

15.

Al-mashaleh M, Bak H, Moore J, Manolios N, Englert H . Resolution of sclerodermatous myocarditis after autologous stem cell transplantation. Ann Rheum Dis. 2006; 65(9):1247-8. PMC: 1798272. DOI: 10.1136/ard.2005.048405. View

16.

Toldo S, Mezzaroma E, Bressi E, Marchetti C, Carbone S, Sonnino C . Interleukin-1β blockade improves left ventricular systolic/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse. J Cardiovasc Pharmacol. 2014; 64(1):1-6. DOI: 10.1097/FJC.0000000000000106. View

17.

Luca G, Bombace S, Monti L . Heart Involvement in Systemic Sclerosis: the Role of Magnetic Resonance Imaging. Clin Rev Allergy Immunol. 2022; 64(3):343-357. DOI: 10.1007/s12016-022-08923-3. View

18.

Zhang D, Cui Y, Li B, Luo X, Li B, Tang Y . miR-155 regulates high glucose-induced cardiac fibrosis via the TGF-β signaling pathway. Mol Biosyst. 2016; 13(1):215-224. DOI: 10.1039/c6mb00649c. View

19.

Ishizaki Y, Ooka S, Doi S, Kawasaki T, Sakurai K, Mizushima M . Treatment of myocardial fibrosis in systemic sclerosis with tocilizumab. Rheumatology (Oxford). 2020; 60(6):e205-e206. DOI: 10.1093/rheumatology/keaa865. View

20.

Tyndall A, Bannert B, Vonk M, Airo P, Cozzi F, Carreira P . Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010; 69(10):1809-15. DOI: 10.1136/ard.2009.114264. View